Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Inclusion Criteria: * Untreated multiple myeloma requiring treatment * Total cumulative dose of prior doxorubicin can not exceed 240 mg/m2 * Must have measurable disease * Left Ventricular Ejection Fraction (LVEF) \>= 50 % determined by Multiple Gated Acquisition Scan (MUGA) * Karnofsky performance status of \>= 60% * Adequate bone marrow, liver and renal function * Disease-free from prior malignancies \>= 5 years with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * Female participants (if of child bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control. Exclusion Criteria: * Life expectancy of \>= 3 months * Pregnant or breast feeding * History of cardiac disease, with New York Heart Association Class II or greater, with congestive heart failure * or unstable angina, uncontrolled hypertension or cardiac arrythmias or myocardial infarction within the last 6 months * Uncontrolled diabetes mellitus or systemic infection * Nonsecretory myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) or smoldering myeloma * Confusion, disorientation, or history of psychiatric illness which may impair patient's ability to give informed consent * Prior chemotherapy to treat Multiple Myeloma * Prior radiotherapy to an area greater than 1/3 of the skeleton * Prior local radiotherapy within 1 week of treatment * Any investigational agent within 30 days of the first dose of treatment * Prior single agent dexamethasone (or another corticosteroid) to treat Multiple Myeloma.